A novel mechanism behind resistance to angiogenesis inhibitors has now been identified -- drugs that fight cancer by suppressing the formation of new blood vessels. A Massachusetts General Hospital ...

Primary pulmonary nuclear protein of the testis (NUT) midline carcinoma (NMC) is an extremely rare, highly aggressive thoracic malignancy that presents significant diagnostic and therapeutic ...

In 2018, lung cancer caused 1.8 million cancer deaths worldwide. It is the most common type of cancer, with non-small cell lung cancers (NSCLCs) accounting for 85% of lung cancers. Most recent lung ...

Using a mathematical modeling approach, scientists have found that certain parameters of tumor growth in mice can predict the effectiveness of drugs that block formation of tumor-nourishing blood ...

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a ...

The dawn of molecular medicine has brought many new challenges: How do these therapies work in patients? Why do they fail in some patients? Is their mechanism of action in patients the same as in ...

Application of PD-1/PD-L1 immune checkpoint inhibitors treating lung cancer in Yerevan Armenia: Two-center experience. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This ...

The arrival of oral tyrosine kinase inhibitors (TKIs) radically changed the treatment paradigm in EGFR-mutated advanced non-small cell lung cancer (NSCLC), and this was followed by development of next ...

Most tumors release various signaling molecules to support their incessant growth, invasion, and metastasis. Some of these molecules, known as tumor angiogenic factors (TAF), are able to stimulate the ...

– CABOMETYX is the first therapy to demonstrate improved overall survival, progression-free survival and objective response rate in a large, randomized phase 3 trial of patients with advanced kidney ...

Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have identified a new molecular drug ...